Healthwell Acquisition Corp I - Warrants (01/04/2028

(Warrants)
NEW
NAS:HWELW (USA)   Warrants (01/04/2028)
$ 0.00030 (0%) 02:51 PM EST
130.88
P/B:
1.36
Volume:
0
Avg Vol (2M):
0
Volume:
0
Avg Vol (2M):
0

Business Description

Healthwell Acquisition Corp I
NAICS : 551112 SIC : 6719

Share Class Description:

HWELW: Warrants (01/04/2028)
Compare
Compare
PWUPBLUACBRGCHAANNAGTGAADPCSEGGFPORTCITEPBAJSVMBSCRMCVIIAACGHIXALCCAACTDWACSAGA
Traded in other countries / regions
IPO Date
2021-09-23
Description
Healthwell Acquisition Corp I is a blank check company.
Name Current Vs Industry Vs History
Cash-To-Debt
0.17
Equity-to-Asset
0.93
Debt-to-EBITDA
-0.46
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.06
Quick Ratio
0.06
Cash Ratio
0.02

Dividend & Buy Back

Name Current Vs Industry Vs History

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio
130.88
PB Ratio
1.36
EV-to-EBIT
-179.05
EV-to-EBITDA
-179.05
EV-to-FCF
-68.49
Earnings Yield (Greenblatt) %
-0.56
FCF Yield %
-1.46

Financials

HWELW's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:HWELW

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Healthwell Acquisition Corp I Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % -
14-Day RSI -
14-Day ATR ($) -
20-Day SMA ($) -
12-1 Month Momentum % -
52-Week Range ($) 0 - 0.7299
Shares Outstanding (Mil)

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Healthwell Acquisition Corp I Filings

Filing Date Document Date Form
No Filing Data

Healthwell Acquisition Corp I Stock Events

Financials Calendars
Event Date Price ($)
Second quarter earnings results for 2024 2024-08-16 --
General meeting for 2023 2024-07-26 10:30 --
Show
Entries

Healthwell Acquisition Corp I Frequently Asked Questions

What is Healthwell Acquisition Corp I(HWELW)'s stock price today?
The current price of HWELW is $0.00. The 52 week high of HWELW is $0.73 and 52 week low is $0.00.
When is next earnings date of Healthwell Acquisition Corp I(HWELW)?
The next earnings date of Healthwell Acquisition Corp I(HWELW) is .
Does Healthwell Acquisition Corp I(HWELW) pay dividends? If so, how much?
Healthwell Acquisition Corp I(HWELW) does not pay dividend.

Guru Commentaries on NAS:HWELW

No articles.

Press Release

Subject Date
Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate 2023-11-17
Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc. 2023-11-03
Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transactions 2023-10-23
Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions 2023-10-17
Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma 2023-10-04
Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma 2023-09-13
Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma 2023-07-10
Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma 2023-06-12
Starton Therapeutics, Inc. and Healthwell Acquisition Corp. I to Present at the Jefferies Healthcare Conference 2023-06-06
Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments 2023-04-27
10/Page

Articles on Healthwell Acquisition Corp I

No articles.

Headlines

See More
  • 1
No news.
  • 1